News
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
SAN FRANCISCO, (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement for the sale of 23andMe to Regeneron Pharmaceuticals,
The last time we talked about 23andMe’s bankruptcy sale, we suggested you might want to delete your genetic data from the ...
The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...
Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, ...
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar ...
The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback